

# GC/MS Profiling, *In-Vitro* Cytotoxic and Antioxidant Potential of the Essential Oil of *Pulicaria Crispa* (Forssk) Growing in Egypt

Dekinash MF<sup>1</sup>, Abou-Hashem MM<sup>2</sup>, Beltagy AM<sup>1</sup> and El-Fiky FK<sup>3\*</sup>

<sup>1</sup>Department of Pharmacognosy, Damanhour University, Egypt

<sup>2</sup>Department of Pharmacognosy, Zagazig University, Egypt

<sup>3</sup>Department of Pharmacognosy, Delta University for Science and Technology, Egypt

**\*Corresponding author:** Fathy Kandeel El-Fiky, Department of Pharmacognosy, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt, Email: maged\_a\_hashem@hotmail.com

## Research Article

Volume 3 Issue 3

**Received Date:** May 02, 2019

**Published Date:** August 22, 2019

**DOI:** 10.23880/ipcm-16000175

## Abstract

The essential oil EO obtained by hydrodistillation from the aerial parts of *Pulicaria crispa* was profiled using GS/MS analysis. The oil was found to contain carvotanacetone as a major component (81.9%). Biological investigation revealed that the oil possessed EC<sub>100</sub> value of 12.8 µl/ml in the *in-vitro* cytotoxicity assay against peripheral blood mononuclear cells (PBMCs). The oil showed no immune-stimulant activity. The antioxidant potential of the oil was assayed using DPPH radical inhibition resulting in inhibition percentage of 66.19% and trolox equivalent antioxidant capacity (TEAC) of 9.22 µg/ml. The results indicate powerful antioxidant capacity of the oil, which makes it a good candidate to be used as a natural preservative or as a source of natural antioxidants to be incorporated in pharmaceutical applications. The cytotoxicity assay of the oil against colorectal "Caco-2" and hepatocellular "HepG-2" carcinoma cell lines showed IC<sub>50</sub> values of 4.73 and 20.11 µl/ml, respectively. The obtained results spot the light on the colorectal anticancer potential of the oil, which should be subjected to future animal experimental study in form of enema.

**Keywords:** *Pulicaria Crispa*; GC/MS Analysis; Immune-Stimulant; Antioxidant; Anticancer Activity

## Introduction

Herbs containing essential oils (EOs) and their components impressively demonstrate a wide array of potential activities in the fields of therapeutic products, cosmetics, perfumery, food industry and aromatherapy [1]. The genus *Pulicaria*, belongs to the *Inuleae* tribe (Asteraceae), encompasses around 100 species distributed worldwide. Different *Pulicaria* species have been reported to possess impressive biological activities and most of

tribe species have been reported as traditional medicines [2]. Accordingly, various *Pulicaria* species have been thoroughly investigated phytochemically and biologically. *Pulicaria crispa* (Forssk), is often synonymous with *Pulicaria undulata*, *Aster crispus*, and *Francoeuria crispa*. It is an annual herb locally known in Saudi Arabia as "Gethgath". Leaves are sessile, acute to obtuse, undulate to rarely toothed, Heads are hemispherical, heterogamous, radiate, and golden-yellow to orange, 0.5-1 cm across golden-yellow to orange in colour [3,4]. *P. crispa* is

traditionally used by people of southern Egypt and Saudi Arabia to treat inflammation and as an insect repellent. It is also used as an herbal tea [5]. Also, it was reported to be used in Saudi Arabia for bruises, skin infections and gastrointestinal disturbances [6]. Owing to its strong smelling EO, it has been used since ancient times for treatment of sinusitis and respiratory tract infections in the traditional medicine in the southern part of Iran [7].

*Pulicaria crispa* is distributed in Saudi Arabia, Kuwait, Iran, Iraq, Egypt, Afghanistan, Pakistan, India and many parts of north and west tropical Africa [8]. Many studies investigated the chemical composition of essential oil extracted from various *Pulicaria* species in the Middle East region [9-12]. However, to the best of our knowledge, the current study is the first one, performed to investigate the antioxidant, immune-stimulant and cytotoxic activities of the essential oil of *P. crispa* cultivated in Egypt.

## Materials and Methods

### Plant Material

The aerial parts of *Pulicaria crispa* were collected during the flowering stage, in March 2016 from their wild habitat in the western Egyptian desert, El-Sadat city, Al-Menoufia Governorate. The exact location of collection is 30.38182°N, 30.51159°E. The collected aerial parts were air-dried in shade for 7 days, and then pulverized to fine pieces. The plant was kindly verified by Dr. Mohamed El-Azazi; Assistant professor of Plant Ecology in the Environmental Studies and Research Institute, El-Sadat City University. Voucher specimen was kept in the herbarium of Faculty of Pharmacy, Damanhour University as (106P).

### Extraction of the Essential Oil

According to the European Pharmacopoeia 2007, the air-dried finely ground aerial parts of *P. crispa* (200 g) were subjected to hydrodistillation for the extraction of its essential oil using a Clevenger-type distillation apparatus for 3h [13].

The collected essential oil was then dried by passing over anhydrous sodium sulphate and kept away from light, at 4°C in a sealed glass vial, till subsequent analysis.

### Compositional Analysis of Essential Oil by GC/MS

The essential oil of *P. crispa* was analyzed by HP-5890 Series II gas chromatograph, equipped with a flame

ionization detector and a 15 m HP5 column, 0.32 mm ID, 0.25 µm film thicknesses.

GC/MS analysis was performed on Shimadzu GC-MS QP 2010. High purity helium was used as the carrier gas at a constant linear velocity of 43.8 cm/s. The constant flow was controlled by 82.5 KP a pressure giving a total flow of 19.2 ml/min, a column flow of 1.47 ml/min and a purge flow of 3.0 ml/min. The ion source and interface temperatures were 230°C and operated at ionization energy of 70 eV. The QP mass spectrometer was working with mass scan in a range of 40-700 m/z. The used column was Varian capillary column (TR5- CPSIL- 5CB, 5% polydiphenyl 95% dimethylsiloxane), which is 50 m length, 0.32 mm diameter and 1.25 µm film thickness. Column oven temperature programmed from 40°C to 280°C in 10 min. Essential oil samples (20µl) were diluted with methanol (200µl). The injection volume was 1.0 µl. The split ratio was 10 and the injector temperature was 210°C.

### Identification and Quantification of Essential Oil Composition

Identification of components was performed by comparing their relative retention indices (RI) determined with the reference of a homologous series of n-alkanes (C<sub>8</sub> to C<sub>24</sub>) [14,15]. The fragmentation patterns of the mass spectra were compared with the WILEY (<http://eu.wiley.com/WileyCDA/WileyTitle/productCd-04-70047852.html>) and NIST 05 (<http://www.nist.gov/srd/nist1a.htm>) libraries. The linear temperature-programmed RIs of all the constituents were calculated based on the GC through the interpolation between bracketing n-alkanes as follow:

$$RI = 100 [(t_{R(i)} + t_{R(z)}) \times Z / (t_{R(z+1)} - t_{R(z)})]$$

Where Z was the number of carbon atoms in the smaller n-alkane, and  $t_{R(i)}, t_{R(z)}$

And  $t_{R(z+1)}$  were the retention time of the desired compound [16]. Quantitative data of the oil components were obtained from the electronic integration of the FID peak areas

### Preparation of Oil Samples for the Bioactivity Study

Different concentrations of the prepared essential oil (12.5, 6.25, 3.125, 1.5625, 0.78125 and 0.3906 µl/ml) were prepared using DMSO by serial dilution in a 96-well plate; these concentrations were screened for their immune-stimulant and anticancer potential against human

epithelial colorectal adenocarcinoma "Caco-2" and hepatocellular carcinoma "HepG-2" cell lines.

### In-vitro Cytotoxicity Assay

**In-vitro Cytotoxicity Assay on Normal Lymphocytes (Immune stimulant activity screening):** In-vitro cytotoxicity assay was performed to evaluate the viability of normal Human Peripheral Blood Mononuclear cells (PBMCs) after incubation for 72 with the different concentrations of the *P. crispa* essential oil. Viability of the cells was measured using neutral red uptake assay to determine the maximum safe concentration of the oil on normal cells [17].

The results were interpreted to calculate the maximum safe concentration that keeps 100% cell viability ( $EC_{100}$ ) for the essential oil using SPSS 15.0 for windows [18]. Data output was presented as Stimulation Index, which is the ratio of the optical density of lymphocytes stimulated by the tested material to the optical density of control unstipulated lymphocytes after removal of the effect of the blank. A value higher or equal to 1.5 indicates a significant immune-stimulant activity [19].

**Cancer cell lines and culture:** Colorectal adenocarcinoma "Caco-2" (ATCC® Number: HTB-37™), and Hepatocellular carcinoma "HepG-2" (ATCC® Number: HTB-8065™) were **obtained from the American type culture collection. The cells were maintained at 37 °C in** a humidified air incubator containing 5% CO<sub>2</sub>. **The cells were grown in RPMI 1640 medium (MP Biomedicals Inc., Irvine, CA, USA) containing 10% foetal bovine serum (FBS, Logan, UT, USA) as well as 0.2% glucose, 2 mM glutamine.** Mitomycin C (MCC) (0.09 µg/ml) was used as a positive anti-cancer drug control (for HepG-2 cell line caused inhibition by 64% and for Caco-2 cell line caused inhibition by 57%).

The inhibitory effects of essential oil of *P. crispa* on the growth of Caco-2 and HepG-2 cells were evaluated *in vitro* using neutral red uptake assay [17].

The half maximal inhibitory concentration ( $IC_{50}$ ) values were determined from software SPSS 15.0 for windows [18]. Cell inhibition percentage was calculated from the following equation:

$$\text{Cell inhibition (\%)} = 100 - [(E-B/C-E)] \times 100$$

Where:

- E: The mean absorbance of cells exposed to extract.  
B: The mean absorbance of blank control.

C: The mean absorbance of control cells.

### Antioxidant Activity of the Essential Oil

The antioxidant capacity of *P. Crispa* EO was determined using a test based on the redox potential of DPPH (Sigma-Aldrich, St. Louis, MO, USA). A 1 mM DPPH solution (0.394 mg/mL) in methanol was prepared and then diluted 1:10 to obtain a 100 µM solution (Abs at 515nm = 0.5-0.6). 500 µl of the sample and 500µl of 100 µM DPPH solution were mixed in a cuvette and a negative control with 500 µl of methanol and 500µl of DPPH solution was also prepared. Both solutions were incubated in the dark at room temperature for 15min. Absorbance was read at  $\lambda = 515$  nm using methanol as blank.

The results were expressed as the percentage reduction in the radical absorbance [20].  
(Abs max (negative control) - (Abs sample+ DPPH) x 100  
Abs max

The oil concentrations used for the DPPH assay is chosen based on the cytotoxicity experiment on normal cells; where the maximum safe concentration ( $EC_{100}$ ) used is 12.8 µl/ml.

The antioxidant potential of the oil was compared to a reference antioxidant agent which is trolox; the results will be expressed as trolox equivalent antioxidant capacity (TEAC). Calibration curve between inhibition percentage and concentrations of trolox 12.5-0.3 µg/ml was constructed. The good linearity was proven by the high value of the correlation coefficient; which was found to be 0.9915. By substituting inhibition percentage of the tested essential oils in the regression equation of the calibration curve, TEAC of the oil was computed.

## Results and Discussion

### The Essential Oil Yield

The hydro distillation of 200g of the ground aerial parts of *P. crispa* yielded 1.2 ml EO with sweet odour, yellowish green colour with density lighter than water and a yield of 0.6 % (V/W).

### Chemical Composition of Essential Oil of *P. crispa*

The GC/MS analysis of the essential oil of *P. Crispa* exhibited eight major components is represented in (Table 1). All the identified oil components were dominated by oxygenated monoterpenes type. The major component of *P. Crispa* EO was carvotanacetone, representing 81.99 % of

the total oil components. The relatively high percentage of carvotanacetone, was in a good agreement with previous studies on the EO of *P. crispata* collected from the Middle East region [7,9,10,21,22] but differs with those from Iran. The essential oils of *P. undulata* cultivated in Iran did not contain carvotanacetone at all [23-25].

No.	Compounds <sup>a</sup>	Relative area percentage (%)	RI*
1	Isothujol	1.60	1079
2	$\beta$ -linalool	5.34	1082
3	Chrysanthenone	6.87	1119
4	Carvotanacetone	81.99	1158
5	$\alpha$ -Methyl- $\alpha$ -[4-methyl-3-pentenyl] oxiranemethanol	1.10	1182
6	2-(1-methyl-2-oxopropyl)cyclohexanone	0.69	1322
7	cis-Jasmone	0.35	1338
8	4-Oxatricyclo [4.3.1.1(3,8)]undecan-5-one	2.06	1349

**Table 1:** Chemical composition of *P. crispata* essential oil.

RI\* Kovats retention indices calculated relative to homologous series of n-alkanes determined by GC-MS QP2010 on a TR5- CPSIL- 5CB column.

The oil also contained chrysanthenone (6.87%),  $\beta$ -linalool (5.34%), 4-oxatricyclo [4.3.1.1(3,8)]undecan-5-one (2.06%), isothujole (1.6%),  $\alpha$ -methyl- $\alpha$ -[4-methyl-3-pentenyl] oxiranemethanol (1.1%), 2-(1-methyl-2-oxopropyl)cyclohexanone (0.69%) and cis-jasmone (0.35%).

However, the study by Ross et al. (1997) showed some qualitative and quantitative differences in the oil composition than what obtained in our study [21]. This was attributed to the difference in geographical origin of the plant which was collected from Elba Mountain in the South Eastern Egyptian coast.


### Bioactivity Study of the Essential Oil

**Immune Stimulant Activity Screening:** The results of *in-vitro* cytotoxic activity of *P. crispata* oil on human peripheral blood mononuclear cells (Table 2) were expressed in terms of maximum safe concentration that keeps 100% cell viability ( $EC_{100}$ ), which was found to be 12.8  $\mu$ l/ml; however, the effective concentration that kills 50 % of the cells ( $EC_{50}$ ) was 38.61  $\mu$ l/ml.

	Concentration ( $\mu$ l/ml)				
	25	12.5	6.25	3.125	1.5625
Average absorbance	1.0335	1.2505	1.4805	1.6785	1.776
Cell viability percentage	64.9864	78.6313	93.0937	105.544	111.675
Actual cell viability percentage	80.2243	93.8692	108.332	120.782	126.913

**Table 2:** Cytotoxic activity of different concentrations of essential oil on PBMCs.


The essential oils of *P. crispata* showed stimulation indices lower than 1.5 for all the tested concentrations as shown in Figure 1. Accordingly, the essential oil of *P. crispata* cultivated in Egypt proved to exhibit no immune-stimulant activity.



**Figure 1:** Stimulation indices for different concentrations of *P. crispata* essential oil.

**Antioxidant activity:** The percentage reduction in the absorbance of the DPPH radical based on the highest safe dose ( $EC_{100}$ ) is computed to be 66.193% which indicates a powerful antioxidant capacity. The percentage scavenging of DPPH radical is then expressed as "trolox equivalent antioxidant capacity (TEAC) and found to be about 9.220086546  $\mu$ g/ml from the constructed calibration curve (Figure 2). This means that the highest percentage scavenging activity obtained by the oil was found to be equivalent to the antioxidant potential of 9.220086546  $\mu$ g/ml of trolox.

This finding indicates that the essential oil of *P. crispata* can be regarded as a powerful antioxidant agent.




**Figure 2:** Calibration curve of the % inhibition of DPPH radical by Trolox versus the applied concentration range (12.5-0.3 µg/ml).

### Cytotoxic Activity on Cancer Cell Lines

The essential oil of *P. crispata* showed high anticancer efficacy against human colorectal adenocarcinoma (Caco-2) with high  $IC_{50}$  value of 4.73 µl/ml; whereas a slightly lower anticancer efficacy against hepatocellular cancer cell line (HepG-2) was observed with  $IC_{50}$  values of 20.11 µl/ml (Figure 3). These interesting activities, of the investigated oil may be attributed to its high content of carvotanacetone, according to previous reports [26,27].

Moreover, the percentage inhibition of the maximum safe concentration ( $EC_{100}$ =12.8 µl/ml) of *P. crispata* EO on Caco-2 and HepG-2 cell lines were computed to be 97.224 and 33.3022 %.



**Figure 3:** Cytotoxic activity of the essential oil of *P. crispata* on Caco-2 and HepG-2 cell lines.

**Safety and selectivity of *P. crispata* oil as candidate anticancer drug:** It is important to establish that the candidate anticancer drug has cytotoxic activity at concentrations that can be achieved *in-vivo* without

inducing toxic effects to normal cells. The relative effectiveness of the candidate anticancer drug in inhibiting cancerous cells compared to inducing normal cell death is defined as the “Therapeutic or Selectivity Index” and can be calculated using the following expression [28].

$$S.I. = \frac{EC50 \text{ value}}{IC50 \text{ value}}$$

It is desirable to have a high therapeutic index giving maximum anticancer activity with minimal normal cell toxicity. Studies determining cytotoxicity and therapeutic indices should be conducted before the initiation of phase (I) clinical studies. Candidate drugs with greater SI values are considered to be better lead compounds than those with relatively lower values [28, 29].

*P. crispata* oil was found to have SI of 8.163 against colorectal adenocarcinoma, which is higher than that against hepatocellular carcinoma (SI=1.92). Accordingly, this oil may provide a more sufficient therapeutic activity with a comfortable safety margin in the treatment of colorectal cancer than hepatocellular carcinoma. *P. crispata* EO can be considered to be a potential anticancer candidate against colorectal cancer. Future investigation on the use of the oil as an enema for the treatment of colorectal cancer in rats is worth experiment.

### Conclusion

The composition of *P. crispata* essential oil was investigated using GC/MS analysis, which revealed that the oil was characterized by a high content of oxygenated monoterpenes with carvotanacetone as the major component. Regarding the biological investigation of the oil, the essential oil of *P. crispata* showed high anticancer efficacy against human colorectal adenocarcinoma (Caco-2) and a slightly lower anticancer efficacy against hepatocellular cancer cell line (HepG-2). These interesting effects, of the investigated oil may be attributed to its high content of carvotanacetone. The oil was also found to possess a strong antioxidant capacity but showed no immune-stimulant activity. Thus, the oil can be regarded as a potential anticancer candidate against colorectal cancer, the finding which necessitates further future experimentations.

### References

1. Shiratsuchi H, Chang S, Wei A, El Ghorab AH, Shibamoto T (2012) Biological Activities of Low-Molecular Weight Compounds Found in Foods and Plants. *Journal of Food and Drug Analysis* 20: 359-365.

2. Liu LL, Yang JL, Shi YP (2010) Phytochemicals and biological activities of *Pulicaria* species. *Chemistry and Biodiversity* 7(2): 327-349.
3. Chaudhary SA (2001) Flora of the Kingdom of Saudi Arabia, National Agriculture research center-Riyadh 2(1): 342-354.
4. Mandaville JP (1990) Flora of Eastern Saudi Arabia, London: Kegan Paul Int 102(5-6): 444-444.
5. Stavri M, Mathew KT, Gordon A, Shnyder SD, Falconer RA, et al. (2008) Guaianolide sesquiterpenes from *Pulicaria crispa* (Forssk.) Oliv *Phytochemistry* 69(9): 1915-1918.
6. Zoghet M, Al Alsheikh (1999) A Wild Plants in the region of Riyadh, King Saud University Academic Publishing and Press. Riyadh. Saudi Arabia.
7. Bastan M, Sadeghi H (2015) Essential oil variations among the natural populations of *Francoeuria undulata*. *Progress in Biological Sciences* 5: 85-96.
8. Ib Friis (2015) Boulos L (2002) Flora of Egypt: volume 3.(Verbenaceae-Compositae), Cairo: Al Hadara Publishing 22(4): 390-390.
9. Ali NA, Sharopov FS, Alhaj M, Hill GM, Porzel A, et al. (2012) Chemical composition and biological activity of essential oil from *Pulicaria undulata* from Yemen. *Natural Product Communications* 7(2): 257-260.
10. Boumara FM, Mekkiou R, Benyahia S, Chalchat JC, Chalard P, et al. (2016) Essential Oil Composition of *Pulicaria undulata* (L.) (Asteraceae) Growing in Algeria. *International Journal of Pharmacognosy and Phytochemical Research* 8: 746-749.
11. Hanbali FE, Akssira M, Ezoubeyri A, Mellouki F, Benherraif A, et al. (2005) Chemical composition and antibacterial activity of essential oil of *Pulicaria odora* L. *Journal of Ethnopharmacology* 99(3): 399-401.
12. Mossa JS, Hifnawy MS, Al Yahya MA, Al Meshall A, Mekkawi AG (1987) Aromatic Plants of Saudi Arabia-Part 8-\* GC/MS Analysis of Essential Oils of *Pulicaria arabica* and *P. undulata*. *International Journal of Crude Drug Research* 25(2): 113-119.
13. Clevenger JF (1928) Apparatus for the determination of volatile oil. *Journal of the American Pharmaceutical Association* 17(4): 345-349.
14. Davies NW (1990) Gas chromatographic retention indices of monoterpenes and sesquiterpenes on methyl silicon and Carbowax 20M phases. *J Chromatogr A* 503: 1-24.
15. Paolini J, Costa J, Bernardini AF (2005) Analysis of the essential oil from aerial parts of *Eupatorium cannabinum* subsp. *corsicum* (L.) by gas chromatography with electron impact and chemical ionization mass spectrometry. *J Chromatogr A* 1076(1-2): 170-178.
16. Jalali Heravi M, Moazeni Pourasil RS, Sereshti H (2015) Elimination of chromatographic and mass spectrometric problems in GC-MS analysis of lavender essential oil by multivariate curve resolution techniques: improving the peak purity assessment by variable size moving window-evolving factor analysis. *J Chromatogr B Analyt Technol Biomed Life Sci* 983: 83-89.
17. Fotakis G, Timbrell JA (2006) In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. *Toxicology Letters* 160(2): 171-177.
18. Green SB, Salkind NJ (2010) Using SPSS for Windows and Macintosh: Analyzing and understanding data: Prentice Hall Press.
19. Beutner KR, Morag A, Deibel R, Morag B, Raiken D, et al. (1978) Strain-specific local and systemic cell-mediated immune responses to cytomegalovirus in humans. *Infection and Immunity* 20(1): 82-87.
20. Nahar L, Russel WR, Middleton M, Shoeb M, Sarker SD (2005) Antioxidant phenylacetic acid derivatives from the seeds of *Ilex aquifolium*. *Acta Pharmaceutica* 55(2): 187-193.
21. Ross SA, El Sayed KA, El Sohly MA, Hamann MT, Abdel Halim OB, et al. (1997) Phytochemical analysis of *Geigeria alata* and *Francoeuria crispa* essential oils. *Planta Medica* 63(5): 479-482.
22. EL Kamali HH, Yousif MO, Ahmed O, Sabir S (2009) Phytochemical analysis of the essential oil from aerial parts of *Pulicaria undulata* (L.) Kostel from Sudan. *Ethnobotanical Leaflets* 13(4): 467-471.
23. Rav M, Valizadeh J, Noroozifar M, Khorasani Motlagh M (2011) Screening of chemical composition of essential oil, mineral elements and antioxidant activity in

- Pulicaria undulata (L.) CA Mey from Iran. Journal of Medicinal Plants Research 5(10): 2035-2040.
24. Nematollahi F, Rustaiyan A, Larijani K, Nadimi M, Masoudi S (2006) Essential Oil Composition of Artemisia biennisz Willd. and Pulicaria undulata (L.) CA Mey., Two Compositae Herbs Growing Wild in Iran. Journal of Essential Oil Research 18(3): 339-341.
25. Javadinamin A, Asgarpanah J (2014) Essential Oil Composition of *Francoeuria undulata* (L.) Lack. Growing Wild in Iran. Journal of Essential Oil Bearing Plants 17(5): 875-879.
26. Zheng GQ, Kenney PM, Luke KT (1992) Effects of carvone compounds on glutathione s-transferase activity in a/j mice. J Agr Food Chem 40: 751-755.
27. Fawzy GA, Al Ati HY, El Gamal AA (2013) Chemical composition and biological evaluation of essential oils of *Pulicaria jaubertii*. Pharmacognosy Mag 9(33): 28-32.
28. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA A Cancer Journal for Clinicians 61(2): 69-90.
29. Rahman AU (2012) Studies in natural products chemistry. New York, Wiley, Elsevier 64: 1-567.

